By using this site, you agree to the Privacy Policy and Terms of Use.
Accept

Theindiabizz

Startup and Entrepreneurship Stories, as well as a Leadership Story

  • Explore
    • India
    • Business
    • Venture capital
    • Private equity
    • Product Roadmap
  • News
    • Market
    • acquisition
    • Funding
    • energy
    • Automobile
  • Industry
    • Beauty Sector
    • Entertainment
    • Hotel Industry
    • Enterprise IT
    • Property
    • Consumer Internet
    • Tech
    • E commerce
    • Agency
    • Edtech startup
    • Banking Sector
  • Health
  • Leadership
Search
More
  • Her Story
  • Interview
  • Art And Culture News
  • Women Power
  • cryptocurrency
  • current affairs
  • Investor Pitch Deck
  • List of Indian VCs
  • List Of Investors In India
  • pr-newswire
  • Press release
  • Raise fund
  • Submit Startup
  • Government
  • Economy
  • Entertainment
  • Sport
  • Property
Reading: Mauritius Based LTS Investment Fund Picks up Stake in Bliss GVS Pharma Ltd.
Share
Notification Show More
Latest News
TPG backed InsurTech PolicyBoss closes Series B with India SME Investments amongst a consortium of investors
TPG backed InsurTech PolicyBoss closes Series B with India SME Investments amongst a consortium of investors
June 6, 2023
Indian cricketer KL Rahul becomes an investor in HyugaLife, a startup backed by Sequoia.
Indian cricketer KL Rahul becomes an investor in HyugaLife, a startup backed by Sequoia.
June 6, 2023
Rs 280 Cr Vanished As Another Indian Startup Founder Enjoyed Lavish Lifestyle
Rs 280 Cr Vanished As Another Indian Startup Founder Enjoyed Lavish Lifestyle
June 4, 2023
Bengaluru landlord makes a noteworthy move by investing $10,000 in their tenant's startup
Bengaluru landlord makes a noteworthy move by investing $10,000 in their tenant’s startup
June 4, 2023
Spectacom Global has successfully raised Rs 11 crore in pre-Series A funding
Spectacom Global has successfully raised Rs 11 crore in pre-Series A funding
June 2, 2023
Aa
Aa
TheindiabizzTheindiabizz
  • Business
  • Politics
  • Funding
  • Health
  • Science
  • Fashion
  • acquisition
  • Agency news
  • Beauty Sector
Search
  • Explore
    • India
    • Business
    • Venture capital
    • Private equity
    • Product Roadmap
  • News
    • Market
    • acquisition
    • Funding
    • energy
    • Automobile
  • Industry
    • Beauty Sector
    • Entertainment
    • Hotel Industry
    • Enterprise IT
    • Property
    • Consumer Internet
    • Tech
    • E commerce
    • Agency
    • Edtech startup
    • Banking Sector
  • Health
  • Leadership
Have an existing account? Sign In
Follow US
Business

Mauritius Based LTS Investment Fund Picks up Stake in Bliss GVS Pharma Ltd.

Editor Desk
By Editor Desk Published January 13, 2021
Last updated: 2021/01/13 at 11:20 AM
Share
SHARE

As per Bulk deal data available on NSE, Mauritius based LTS Investment Fund has picked up stake in BSE and NSE listed Bliss GVS Pharma Ltd. Earlier, Life Corporation of India (LIC) had also raised stake in Bliss GVS Pharma.

Bliss GVS is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. Today Bliss GVS is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest product portfolio in this segment.

- Advertisement -

The company’s thirty years of experience in suppository manufacturing has resulted in developing an extensive product offering in suppositories and pessaries across various therapeutic categories. Bliss GVS manufacturing plants are certified to be cGMP compliant by local and international standards: EU GMP, WHO GMP, OHSAS-18001 : 2007 and ISO-14001 : 2004. This company is the only EU-GMP certified suppositories manufacturer in India.

It is constantly looking to raise the bar in terms of developing innovative products and quality standards which keeps it ahead of competition in this dosage form. This organisation is proud of its segment leadership in Anti-malarial products across most African markets. Its brands cover an extensive range of Artemisinin-based combination formulations across various dosage forms – Tablets, Suspensions, Sachets, Suppositories and Injections.

The company’s sales and Profit before tax have constantly been rising since FY14-15. The company has received many accreditations including “Outstanding Export Performance Award” by Pharmexil, “National Award for Research and Development efforts” and “National Award for Outstanding Efforts in Entrepreneurship“.

Bliss GVS Pharma has 8 manufacturing facilities, over 20 therapeutic categories and over 250 products. Over the last decade, Bliss GVS has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities. The company is poised for an accelerated rate of growth.